Valuation: MedinCell S.A.

Market Cap 878M 1.02B 826M 751M 1.41B 97.44B 1.43B 9.69B 3.8B 48.74B 3.82B 3.74B 162B P/E 2027 *
408x
P/E 2028 * 51.4x
Enterprise Value 864M 1B 812M 738M 1.39B 95.8B 1.41B 9.53B 3.73B 47.91B 3.75B 3.67B 160B EV / Sales 2027 *
19.6x
EV / Sales 2028 * 14.4x
Free-Float
66.02%
Yield 2027 *
-
Yield 2028 * -
1 day+4.58%
1 week-0.25%
Current month-7.46%
1 month-3.14%
3 months-3.99%
6 months+2.29%
Current year-2.19%
1 week 23.28
Extreme 23.28
24.2
1 month 23.28
Extreme 23.28
26.02
Current year 19.49
Extreme 19.49
28.76
1 year 16.3
Extreme 16.3
37.82
3 years 5.51
Extreme 5.51
37.82
5 years 4.74
Extreme 4.735
37.82
10 years 4.31
Extreme 4.31
37.82
Manager TitleAgeSince
Chief Executive Officer 62 2003-01-08
Director of Finance/CFO 52 2023-08-31
Chief Tech/Sci/R&D Officer 67 2022-05-08
Director TitleAgeSince
Director/Board Member 62 2003-01-08
Chairman - 2024-03-12
Director/Board Member - 2016-05-24
Change 5-day change 1-year change 3-year change Capi.($)
+4.58%-0.25% - - 1.02B
+3.94%+5.65%+83.34%+134.39% 1,093B
+1.10%+5.61%+54.95%+64.62% 653B
+1.91%+6.62%+28.64%+76.64% 458B
+1.62%+0.57%+41.28%+44.55% 355B
+1.04%+2.33%+25.97%+41.22% 294B
+2.48%+3.52%+2.82%+13.49% 248B
+3.45%+5.93%+49.17%+69.11% 230B
+1.25%+0.77%-13.29%-52.14% 203B
+3.10%+9.02%+25.56%+95.06% 178B
Average +2.47%+1.20%+33.16%+54.11% 412.27B
Weighted average by Cap. +2.47%+1.45%+47.48%+74.81%

Financials

2027 *2028 *
Net sales 44.14M 51.11M 41.53M 37.75M 71M 4.9B 72.04M 487M 191M 2.45B 192M 188M 8.16B 58.92M 68.22M 55.44M 50.39M 94.77M 6.54B 96.16M 650M 255M 3.27B 256M 251M 10.89B
Net income 667K 772K 627K 570K 1.07M 73.96M 1.09M 7.36M 2.88M 36.99M 2.9M 2.84M 123M 13.33M 15.43M 12.54M 11.4M 21.43M 1.48B 21.75M 147M 57.64M 739M 57.93M 56.67M 2.46B
Net Debt -14.87M -17.21M -13.99M -12.71M -23.91M -1.65B -24.26M -164M -64.3M -825M -64.63M -63.22M -2.75B -30.53M -35.35M -28.73M -26.11M -49.11M -3.39B -49.83M -337M -132M -1.69B -133M -130M -5.64B
Logo MedinCell S.A.
MedinCell S.A. is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2026, the company had a portfolio of a product in phase III clinical development and 3 products in preclinical development.
Employees
141
Date Price Change
26-08-19 24.08 +2.03%
26-08-18 €23.60 +0.85%
26-08-17 €23.40 +0.09%
26-08-14 €23.38 -3.07%
26-08-13 €24.12 -0.08%
Trader
Investor
Global
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.46EUR
Average target price
34.51EUR
Spread / Average Target
+41.09%

Quarterly revenue - Rate of surprise